<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37389590</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Incidence and prevalence of Spinal and bulbar muscular atrophy in South Korea: a nationwide population-based study.</ArticleTitle><Pagination><StartPage>5017</StartPage><EndPage>5022</EndPage><MedlinePgn>5017-5022</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11842-8</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA), or Kennedy's disease, is a rare X-linked neuromuscular disorder predominantly affecting males and caused by a mutation in the androgen receptor gene. The epidemiology and comorbidities associated with SBMA in different ethnicities remain poorly understood. This study investigated the prevalence, incidence, and comorbidities associated with SBMA in the South Korean population using the Health Insurance Review and Assessment Service (HIRA) database. We retrospectively reviewed diagnosed cases of SBMA (G12.25 code of the Korean Classification of Diseases-7th edition) registered from January 1, 2016, to December 31, 2019, to calculate incidence and prevalence rates and concomitant comorbidities. Additionally, we surveyed SBMA patients (questionnaire group) visiting our clinic in 2022 to compare comorbidities with the HIRA data. The mean incidence rate of SBMA in the Korean population was 0.36/100,000 males from 2018 to 2019, while the prevalence rate was approximately 0.46/100,000 males from 2016 to 2019. The most common comorbidities identified in HIRA were gastritis and duodenitis (99.7%), gastroesophageal reflux (90.5%), hyperlipidemia (88.4%), and liver disorders (75.2%), which showed similar results in the questionnaire group. Additionally, gastric cancer was the most common type of cancer reported in SBMA in South Korea; although indeterminate, age-related factors may contribute to the development of cancer in these patients. Our findings provide valuable insights into the epidemiology and associated comorbidities of SBMA within the Korean population, which could inform clinical practice and future clinical research.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Mo</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Dongguk University College of Medicine, Dongguk University Gyeongju Hospital, Gyeongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Minsung</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyungpook National University Chilgok Hospital, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Sung</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-5506-9206</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Kyungpook National University Chilgok Hospital, Daegu, South Korea. neurojspark@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Hoguk-ro 807, Buk-gu, Daegu, South Korea. neurojspark@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">National health insurance service</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">South Korea</Keyword><Keyword MajorTopicYN="N">Spinal and bulbar muscular atrophy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>30</Day><Hour>13</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>30</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37389590</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11842-8</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11842-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352(6330):77&#x2013;79. https://doi.org/10.1038/352077a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/352077a0</ArticleId><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M et al (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129:1446&#x2013;1455. https://doi.org/10.1093/brain/awl096</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl096</ArticleId><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold FJ, Merry DE (2019) Molecular mechanism and therapeutics for SBMA/Kennedy&#x2019;s disease. Neurotherapeutics 16:928&#x2013;947. https://doi.org/10.1007/s13311-019-00790-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00790-9</ArticleId><ArticleId IdType="pubmed">31686397</ArticleId><ArticleId IdType="pmc">6985201</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejager S, Bry-Gauillard H, Bruckert E et al (2002) A comprehensive endocrine description of Kennedy&#x2019;s disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 87:3893&#x2013;3901. https://doi.org/10.1210/jcem.87.8.8780</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.87.8.8780</ArticleId><ArticleId IdType="pubmed">12161529</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Nirmalananthan N, Masset L et al (2014) Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology 82(23):2077&#x2013;2084. https://doi.org/10.1212/WNL.0000000000000507</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000507</ArticleId><ArticleId IdType="pubmed">24814851</ArticleId><ArticleId IdType="pmc">4075620</ArticleId></ArticleIdList></Reference><Reference><Citation>Udd B, Juvonen V, Hakamies L et al (1998) High prevalence of Kennedy&#x2019;s disease in Western Finland &#x2013; is the syndrome underdiagnosed? Acta Neurol Scand 98(2):128&#x2013;133. https://doi.org/10.1111/j.1600-0404.1998.tb01732.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1998.tb01732.x</ArticleId><ArticleId IdType="pubmed">9724012</ArticleId></ArticleIdList></Reference><Reference><Citation>Leckie JN, Joel MM, Martens K et al (2021) Highly elevated prevalence of spinobulbar muscular atrophy in indigenous communities in Canada due to a founder effect. Neurol Genet. 7(4):e607. https://doi.org/10.1212/NXG.0000000000000607</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000607</ArticleId><ArticleId IdType="pubmed">34250227</ArticleId><ArticleId IdType="pmc">8267784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim L, Kim JA, Kim S (2014) A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health 36:e2014008</Citation><ArticleIdList><ArticleId IdType="doi">10.4178/epih/e2014008</ArticleId><ArticleId IdType="pubmed">25078381</ArticleId><ArticleId IdType="pmc">4151963</ArticleId></ArticleIdList></Reference><Reference><Citation>KOICD disease classification center. https://www.koicd.kr/kcd/guide.do?degree=07 . Accessed 23 Feb 2014</Citation></Reference><Reference><Citation>Korean statistical information service, KOSIS statistical database. https://kosis.kr/statisticsList/statisticsListIndex.do?parentId=A.1&amp;vwcd=MT_ZTITLE&amp;menuId=M_01_01#content-group . Accessed 20 June 2014</Citation></Reference><Reference><Citation>Kang MG, Gwak DW, Cho HJ, Min YS, Park JS (2021) Effect of leuprorelin in bulbar function of spinal and bulbar muscular atrophy patients: observational study for 1 year. J Neurol 268(9):3344&#x2013;3351. https://doi.org/10.1007/s00415-021-10503-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10503-y</ArticleId><ArticleId IdType="pubmed">33675422</ArticleId></ArticleIdList></Reference><Reference><Citation>Guber RD, Takyar V, Kokkinis A et al (2017) Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy. Neurology 89(24):2481&#x2013;2490. https://doi.org/10.1212/WNL.0000000000004748</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004748</ArticleId><ArticleId IdType="pubmed">29142082</ArticleId><ArticleId IdType="pmc">5729799</ArticleId></ArticleIdList></Reference><Reference><Citation>Francini-Pesenti F, Querin G, Martini C, Mareso S, Sacerdoti D (2018) Prevalence of metabolic syndrome and non-alcoholic fatty liver disease in a cohort of italian patients with spinal-bulbar muscular atrophy. Acta Myol 37(3):204&#x2013;209</Citation><ArticleIdList><ArticleId IdType="pubmed">30838350</ArticleId><ArticleId IdType="pmc">6390113</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bertolin C, Da Re E et al (2016) Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J Neurol Neurosurg Psychiatry 87(8):810&#x2013;816. https://doi.org/10.1136/jnnp-2015-311305</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311305</ArticleId><ArticleId IdType="pubmed">26503015</ArticleId></ArticleIdList></Reference><Reference><Citation>Langenbruch L, Perez-Mengual S, Glatz C, Young P, Boentert M (2021) Disorders of sleep in spinal and bulbar muscular atrophy (Kennedy&#x2019;s disease). Sleep Breath 25(3):1399&#x2013;1405. https://doi.org/10.1007/s11325-020-02253-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11325-020-02253-4</ArticleId><ArticleId IdType="pubmed">33219909</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean HE, Brown RW, Beilin J, Warne GL, Zajac JD (2004) Increased frequency of long androgen receptor CAG repeats in male breast cancers. Breast Cancer Res Treat 88:239&#x2013;246. https://doi.org/10.1007/s10549-004-0781-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-004-0781-6</ArticleId><ArticleId IdType="pubmed">15609126</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Atamna H, Zakharov MN, Bhasin S, Khan SH, Jasuja R (2011) Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy. Life Sci 88:565&#x2013;571. https://doi.org/10.1016/j.lfs.2011.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2011.01.021</ArticleId><ArticleId IdType="pubmed">21284948</ArticleId></ArticleIdList></Reference><Reference><Citation>Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H (2018) BRCA2-associated prostate cancer in a patient with spinal and bulbar muscular atrophy. JCO Precis Oncol 2:1&#x2013;10. https://doi.org/10.1200/PO.18.00115</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.18.00115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji J, Sundquist K, Sundquist J (2012) Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden. Lancet Oncol 13(6):642&#x2013;648. https://doi.org/10.1016/S1470-2045(12)70132-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(12)70132-8</ArticleId><ArticleId IdType="pubmed">22503213</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>